Molecure stock reports KITE progress after funding

Published on 09/23/2026 at 23:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Molecure stock traded at PLN 7.45 on September 23, 2026, down 4.49 percent from the prior close. The KITE study reached 30 patients, while a second interim analysis targets 50.

Molecure stock, biotechnology, KITE study, OATD-01, Warsaw Stock Exchange, Illustration mit AI erstellt.

Molecure (ISIN PLONCTH00011) stood at PLN 7.45 on the Warsaw Stock Exchange on September 23, 2026, down 4.49 percent from the prior close. The clinical-stage biotechnology company is advancing its KITE study for OATD-01 after an interim review of the first 30 patients.

KITE study reaches 30 patients

According to Comparic, the Independent Data Monitoring Committee reviewed safety and efficacy data after 12 weeks of treatment in the first 30 patients. The committee recommended continuing the study without changes to its protocol.

The next interim analysis is being prepared around a total of 50 patients, according to Comparic. That figure matters because the study is moving from its first interim checkpoint toward a larger data set for the OATD-01 program.

Funding adds PLN 5 per share

Molecure completed a Series K issue comprising 4,120,631 new shares at PLN 5 per share, as reported by Comparic. The financing gives the company additional capital while increasing the number of shares outstanding.

Molecure's investor page identifies OATD-01 as its most advanced proprietary candidate and describes it as a dual chitinase inhibitor for sarcoidosis and idiopathic pulmonary fibrosis. The company also lists OATD-02 in Phase I development and has scheduled publication of its half-year 2026 report for September 30, 2026, according to its Molecure investor overview.

Stock remains below yearly high

Molecure stock was 17.6 percent below its 52-week high of PLN 9.04 on September 23, 2026, while its 52-week low stood at PLN 4.98. The same session showed a day range of PLN 7.40 to PLN 7.83, placing the price near the lower end of that range.

The market capitalization was PLN 184,192,206 on September 23, 2026. For investors, the next measurable checkpoints are the 50-patient interim data set and the company's scheduled half-year report.